Abstract
Bepotastine besilate, a second-generation antihistamine, is characterized by its rapid absorption after oral administration and immediate clinical responses in patients with chronic urticaria. To confirm its effectiveness, 46 patients diagnosed with chronic urticaria were given bepotastine besilate, and questionnaires were filled out in interviews with doctors for evaluation of the patients' state regarding the frequency of itching and time till clinical response on their first and second visits. Itching, sleepiness, and level of disability were evaluated using the visual analogue scale (VAS). Seventy percent of the patients experienced clinical efficacy of bepotastine besilate treatment within 1 hour of administration. In the VAS assessment, itching was significantly ameliorated and the level of disability significantly decreased by bepotastine besilate treatment. Sleepiness was comparable before and after the start of treatment. This report shows using VAS assessment that bepotastine besilate treatment improves the quality of life of patients with chronic urticaria. We concluded that bepotastine besilate is a useful drug for symptomatic and preventive treatment of chronic urticaria.
| Original language | English |
|---|---|
| Pages (from-to) | 513-518 |
| Number of pages | 6 |
| Journal | Skin Research |
| Volume | 6 |
| Issue number | 5 |
| Publication status | Published - Oct 2007 |
All Science Journal Classification (ASJC) codes
- Dermatology
- Infectious Diseases
